|

Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors

RECRUITINGPhase 1Sponsored by Hansoh BioMedical R&D Company
Actively Recruiting
PhasePhase 1
SponsorHansoh BioMedical R&D Company
Started2025-09-23
Est. completion2026-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07186452

Summary

The primary objective of this study is to evaluate the effect of itraconazole on the pharmacokinetics of HS-20093 in patients with advanced solid tumors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Histologically or cytologically confirmed advanced solid tumors that have failed standard therapy or are intolerant to standard treatment.
2. According to RECIST 1.1 criteria, participants must have at least one target lesion.
3. ECOG performance status score of 0-1 with no deterioration within 2 weeks prior to the first dose.
4. Minimum expected survival greater than 12 weeks.

Exclusion Criteria:

1. Patients with a contraindication for receiving itraconazole according to the prescribing information
2. Patients with severe, uncontrolled, or active cardiovascular diseases

Conditions2

Advanced Solid TumorsCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.